CATX Perspective Therapeutics, Inc.

AMEX
$2.52

Perspective Therapeutics, Inc. (CATX) is expected to report earnings on November 12, 2026, after the market close. The consensus earnings estimate is a loss of $0.24 per share, and the stock has had a Post-Earnings Announcement Drift (PEAD) of -17.4% since its last earnings release on August 10, 2026.

Perspective Therapeutics Beat Consensus Estimates
Monday, August 10, 2026 · 4:22 PM ET
Earnings Date
3rd Quarter, Sep 2026
Nov 12
Thursday · 4:20 PM ET
Earnings Whisper
-
vs ($0.24)
Rev est $200K
Volatility
Enter your expectations below to reveal the current volatility.
Trend Analysis
Expectation
Earnings
Price action
Signals
Score
Sentiment
Grade
Life Cycle
Call Analysis
Earnings-AVWAP $2.99

Sign in or subscribe to unlock sentiment, short interest, and technical indicators.

About Perspective Therapeutics, Inc.

Perspective Therapeutics Inc. is a medical technology and radiopharmaceutical company which provide advanced treatment applications for cancers. The Company is the sole producer of Cesium-131 brachytherapy seeds. Perspective Therapeutics Inc., formerly known as Isoray Inc., is based in RICHLAND, Wash.

Sector

Healthcare

Industry

Biotechnology

Held By 2 ETFs, by dollar flow

Charts powered in part by Lightweight Charts™ by TradingView.